Welcome to our dedicated page for Prothena SEC filings (Ticker: PRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prothena Corporation plc filings document regulatory disclosures for an Irish clinical-stage biotechnology issuer with ordinary shares listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, business highlights, collaboration-related revenue, capital actions such as share repurchase authorization, and board or officer changes.
Proxy materials describe shareholder voting matters, executive compensation and board governance. The company’s filings also record ordinary-share capital matters, including shareholder approval of a capital reduction to create distributable reserves, along with exhibit-based press releases and Inline XBRL cover data.